Liposomal Bupivacaine with Bupivacaine

Phase 3Small molecule

Liposomal Bupivacaine with Bupivacaine is one of 13 small molecule programs targeting Ankle Fracture. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Ankle FractureActive, not recruiting

Ankle FracturePhase 3

Active, not recruiting

Competition

Competitive Landscape

26 competitors in Ankle Fracture

#DrugCompanyPhaseTrials

Aleve

Alnylam Pharmaceuticals

Approved

1 2

Naropin

FFresenius Kabi Oncology Ltd.

Approved

3 3

MS Contin

HHikma Pharmaceuticals LLC

Approved

1 4

Adrenaline

SSamson Clinical Operations Pty Ltd

Approved

1 5

Oxycontin

PProtega

Approved

1 6

Tylenol

Marcaine

1 8

Forsteo

Novartis

Approved

1 9

Bayer Aspirin

Bayer

Phase 1

1 10

Forteo

AAlmaject

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Ankle Fracture1 trial

Liposomal Bupivacaine With Bupivacaine in Ankle Fracture Open Reduction Internal Fixation (ORIF)

Completed·JJamaica Hospital Medical Center·Phase 3·NCT02480621·84 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Liposomal Bupivacaine with Bupivacaine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Liposomal Bupivacaine with Bupivacaine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Liposomal Bupivacaine with Bupivacaine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Jamaica Hospital Medical Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: JJamaica Hospital Medical Center

Liposomal Bupivacaine with Bupivacaine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Ankle Fracture1 trial

References

Drug Info

Quick Facts

Related News